A BILL 
To prohibit prescription drug companies from compensating 
other prescription drug companies to delay the entry 
of a generic drug, biosimilar biological product, or inter-
changeable biological product into the market. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Preserve Access to Af-
4
fordable Generics and Biosimilars Act’’. 
5
01:15 Jun 09, 2021
H2891
2 
•HR 2891 IH
SEC. 2. DECLARATION OF PURPOSES. 
1
The purposes of this Act are— 
2
(1) to enhance competition in the pharma-
3
ceutical market by stopping anticompetitive agree-
4
ments between manufacturers of brand name and 
5
generic drug products or biosimilar biological prod-
6
ucts, or among manufacturers of generic drug prod-
7
ucts or biosimilar biological products, that limit, 
8
delay, or otherwise prevent competition from generic 
9
drugs and biosimilar biological products; and 
10
(2) to support the purpose and intent of anti-
11
trust law by prohibiting anticompetitive practices in 
12
the pharmaceutical industry that harm consumers. 
13
SEC. 3. UNLAWFUL COMPENSATION FOR DELAY. 
14
(a) IN GENERAL.—The Federal Trade Commission 
15
Act (15 U.S.C. 44 et seq.) is amended by inserting after 
16
section 26 (15 U.S.C. 57c–2) the following: 
17
‘‘SEC. 27. PRESERVING ACCESS TO AFFORDABLE GENERICS 
18
AND BIOSIMILARS. 
19
‘‘(a) IN GENERAL.— 
20
‘‘(1) ENFORCEMENT PROCEEDING.—The Com-
21
mission may initiate a proceeding to enforce the pro-
22
visions of this section against the parties to any 
23
agreement resolving or settling, on a final or interim 
24
basis, a patent claim, in connection with the sale of 
25
a drug product or biological product. 
26
01:15 Jun 09, 2021
H2891
3 
•HR 2891 IH
‘‘(2) PRESUMPTION AND VIOLATION.— 
1
‘‘(A) IN
GENERAL.—Subject to subpara-
2
graph (B), in such a proceeding, an agreement 
3
shall be presumed to have anticompetitive ef-
4
fects and shall be a violation of this section if— 
5
‘‘(i) an ANDA filer or a biosimilar bi-
6
ological product application filer receives 
7
anything of value, including an exclusive li-
8
cense; and 
9
‘‘(ii) the ANDA filer or biosimilar bio-
10
logical product application filer agrees to 
11
limit or forgo research, development, man-
12
ufacturing, marketing, or sales of the 
13
ANDA product or biosimilar biological 
14
product, as applicable, for any period of 
15
time. 
16
‘‘(B) 
EXCEPTION.—Subparagraph 
(A) 
17
shall not apply if the parties to such agreement 
18
demonstrate by clear and convincing evidence 
19
that— 
20
‘‘(i) the value described in subpara-
21
graph (A)(i) is compensation solely for 
22
other goods or services that the ANDA 
23
filer or biosimilar biological product appli-
24
cation filer has promised to provide; or 
25
01:15 Jun 09, 2021
H2891
4 
•HR 2891 IH
‘‘(ii) the procompetitive benefits of the 
1
agreement outweigh the anticompetitive ef-
2
fects of the agreement. 
3
‘‘(b) LIMITATIONS.—In determining whether the set-
4
tling parties have met their burden under subsection 
5
(a)(2)(B), the fact finder shall not presume— 
6
‘‘(1) that entry would not have occurred until 
7
the expiration of the relevant patent or statutory ex-
8
clusivity; or 
9
‘‘(2) that the agreement’s provision for entry of 
10
the ANDA product or biosimilar biological product 
11
prior to the expiration of the relevant patent or stat-
12
utory exclusivity means that the agreement is pro-
13
competitive. 
14
‘‘(c) EXCLUSIONS.—Nothing in this section shall pro-
15
hibit a resolution or settlement of a patent infringement 
16
claim in which the consideration that the ANDA filer or 
17
biosimilar biological product application filer receives as 
18
part of the resolution or settlement includes only one or 
19
more of the following: 
20
‘‘(1) The right to market and secure final regu-
21
latory approval for the ANDA product or biosimilar 
22
biological product at a date, whether certain or con-
23
tingent, in the United States prior to the expiration 
24
of— 
25
01:15 Jun 09, 2021
H2891
5 
•HR 2891 IH
‘‘(A) any patent that is the basis for the 
1
patent infringement claim; or 
2
‘‘(B) any patent right or other statutory 
3
exclusivity that would prevent the marketing of 
4
such ANDA product or biosimilar biological 
5
product. 
6
‘‘(2) A payment for reasonable litigation ex-
7
penses not to exceed— 
8
‘‘(A) for calendar year 2019, $7,500,000; 
9
and 
10
‘‘(B) for calendar year 2020 and each cal-
11
endar year thereafter, the amount determined 
12
for the preceding calendar year adjusted to re-
13
flect the percentage increase (if any) in the 
14
Producer Price Index for Legal Services pub-
15
lished by the Bureau of Labor Statistics of the 
16
Department of Labor for the then most recent 
17
12-month period ending December 31. 
18
‘‘(3) A covenant not to sue on any claim that 
19
the ANDA product or biosimilar biological product 
20
infringes a United States patent. 
21
‘‘(d) ENFORCEMENT.— 
22
‘‘(1) ENFORCEMENT.—A violation of this sec-
23
tion shall be treated as an unfair method of competi-
24
01:15 Jun 09, 2021
H2891
6 
•HR 2891 IH
tion under section 5(a)(1) of the Federal Trade 
1
Commission Act (15 U.S.C. 45(a)(1)). 
2
‘‘(2) JUDICIAL REVIEW.— 
3
‘‘(A) IN GENERAL.—Any party that is sub-
4
ject to a final order of the Commission, issued 
5
in an administrative adjudicative proceeding 
6
under the authority of subsection (a)(1), may, 
7
within 30 days of the issuance of such order, 
8
petition for review of such order in— 
9
‘‘(i) the United States Court of Ap-
10
peals for the District of Columbia Circuit; 
11
‘‘(ii) the United States Court of Ap-
12
peals for the circuit in which the ultimate 
13
parent entity, as defined in section 
14
801.1(a)(3) of title 16, Code of Federal 
15
Regulations, or any successor thereto, of 
16
the NDA holder or biological product li-
17
cense holder is incorporated as of the date 
18
that the NDA or biological product license 
19
application, as applicable, is filed with the 
20
Commissioner of Food and Drugs; or 
21
‘‘(iii) the United States Court of Ap-
22
peals for the circuit in which the ultimate 
23
parent entity of the ANDA filer or bio-
24
similar biological product application filer 
25
01:15 Jun 09, 2021
H2891
7 
•HR 2891 IH
is incorporated as of the date that the 
1
ANDA or biosimilar biological product ap-
2
plication is filed with the Commissioner of 
3
Food and Drugs. 
4
‘‘(B) TREATMENT
OF
FINDINGS.—In a 
5
proceeding for judicial review of a final order of 
6
the Commission, the findings of the Commis-
7
sion as to the facts, if supported by evidence, 
8
shall be conclusive. 
9
‘‘(e) ANTITRUST LAWS.—Nothing in this section 
10
shall modify, impair, limit, or supersede the applicability 
11
of the antitrust laws as defined in subsection (a) of the 
12
first section of the Clayton Act (15 U.S.C. 12(a)), and 
13
of section 5 of this Act to the extent that section 5 applies 
14
to unfair methods of competition. Nothing in this section 
15
shall modify, impair, limit, or supersede the right of an 
16
ANDA filer or biosimilar biological product application 
17
filer to assert claims or counterclaims against any person, 
18
under the antitrust laws or other laws relating to unfair 
19
competition. 
20
‘‘(f) PENALTIES.— 
21
‘‘(1) FORFEITURE.—Each party that violates or 
22
assists in the violation of this section shall forfeit 
23
and pay to the United States a civil penalty suffi-
24
cient to deter violations of this section, but in no 
25
01:15 Jun 09, 2021
H2891
8 
•HR 2891 IH
event greater than 3 times the value received by the 
1
party that is reasonably attributable to the violation 
2
of this section. If no such value has been received by 
3
the NDA holder, biological product license holder, 
4
the ANDA filer, or biosimilar biological product ap-
5
plication filer the penalty to the NDA holder, bio-
6
logical product license holder, the ANDA filer, or 
7
biosimilar biological product application filer shall be 
8
sufficient to deter violations, but in no event greater 
9
than 3 times the value given to an ANDA filer or 
10
biosimilar biological product application filer reason-
11
ably attributable to the violation of this section. 
12
Such penalty shall accrue to the United States and 
13
may be recovered in a civil action brought by the 
14
Commission, in its own name by any of its attorneys 
15
designated by it for such purpose, in a district court 
16
of the United States against any party that violates 
17
this section. In such actions, the United States dis-
18
trict courts are empowered to grant mandatory in-
19
junctions and such other and further equitable relief 
20
as they deem appropriate. 
21
‘‘(2) CEASE AND DESIST.— 
22
‘‘(A) IN GENERAL.—If the Commission has 
23
issued a cease and desist order with respect to 
24
a party in an administrative adjudicative pro-
25
01:15 Jun 09, 2021
H2891
9 
•HR 2891 IH
ceeding under the authority of subsection 
1
(a)(1), an action brought pursuant to para-
2
graph (1) may be commenced against such 
3
party at any time before the expiration of 1 
4
year after such order becomes final pursuant to 
5
section 5(g). 
6
‘‘(B) EXCEPTION.—In an action under 
7
subparagraph (A), the findings of the Commis-
8
sion as to the material facts in the administra-
9
tive adjudicative proceeding with respect to the 
10
violation of this section by a party shall be con-
11
clusive unless— 
12
‘‘(i) the terms of such cease and de-
13
sist order expressly provide that the Com-
14
mission’s findings shall not be conclusive; 
15
or 
16
‘‘(ii) the order became final by reason 
17
of section 5(g)(1), in which case such find-
18
ing shall be conclusive if supported by evi-
19
dence. 
20
‘‘(3) CIVIL
PENALTY.—In determining the 
21
amount of the civil penalty described in this section, 
22
the court shall take into account— 
23
‘‘(A) the nature, circumstances, extent, 
24
and gravity of the violation; 
25
01:15 Jun 09, 2021
H2891
10 
•HR 2891 IH
‘‘(B) with respect to the violator, the de-
1
gree of culpability, any history of violations, the 
2
ability to pay, any effect on the ability to con-
3
tinue doing business, profits earned by the 
4
NDA holder, biological product license holder, 
5
the ANDA filer, or biosimilar biological product 
6
application filer, compensation received by the 
7
ANDA filer or biosimilar biological product ap-
8
plication filer, and the amount of commerce af-
9
fected; and 
10
‘‘(C) other matters that justice requires. 
11
‘‘(4) REMEDIES IN ADDITION.—Remedies pro-
12
vided in this subsection are in addition to, and not 
13
in lieu of, any other remedy provided by Federal 
14
law. Nothing in this paragraph shall be construed to 
15
affect any authority of the Commission under any 
16
other provision of law. 
17
‘‘(g) DEFINITIONS.—In this section: 
18
‘‘(1) 
AGREEMENT.—The 
term 
‘agreement’ 
19
means anything that would constitute an agreement 
20
under section 1 of the Sherman Act (15 U.S.C. 1) 
21
or section 5 of this Act. 
22
‘‘(2) AGREEMENT RESOLVING OR SETTLING A 
23
PATENT INFRINGEMENT CLAIM.—The term ‘agree-
24
ment resolving or settling a patent infringement 
25
01:15 Jun 09, 2021
H2891
11 
•HR 2891 IH
claim’ includes any agreement that is entered into 
1
within 30 days of the resolution or the settlement of 
2
the claim, or any other agreement that is contingent 
3
upon, provides a contingent condition for, or is oth-
4
erwise related to the resolution or settlement of the 
5
claim. 
6
‘‘(3) ANDA.—The term ‘ANDA’ means an ab-
7
breviated new drug application filed under section 
8
505(j) of the Federal Food, Drug, and Cosmetic Act 
9
(21 U.S.C. 355(j)) or a new drug application filed 
10
under section 505(b)(2) of the Federal Food, Drug, 
11
and Cosmetic Act (21 U.S.C. 355(b)(2)). 
12
‘‘(4) ANDA FILER.—The term ‘ANDA filer’ 
13
means a party that owns or controls an ANDA filed 
14
with the Food and Drug Administration or has the 
15
exclusive rights under such ANDA to distribute the 
16
ANDA product. 
17
‘‘(5) ANDA 
PRODUCT.—The term ‘ANDA 
18
product’ means the product to be manufactured 
19
under the ANDA that is the subject of the patent 
20
infringement claim. 
21
‘‘(6) BIOLOGICAL
PRODUCT.—The term ‘bio-
22
logical product’ has the meaning given such term in 
23
section 351(i)(1) of the Public Health Service Act 
24
(42 U.S.C. 262(i)(1)). 
25
01:15 Jun 09, 2021
H2891
12 
•HR 2891 IH
‘‘(7) BIOLOGICAL PRODUCT LICENSE APPLICA-
1
TION.—The term ‘biological product license applica-
2
tion’ means an application under section 351(a) of 
3
the Public Health Service Act (42 U.S.C. 262(a)). 
4
‘‘(8) BIOLOGICAL
PRODUCT
LICENSE
HOLD-
5
ER.—The term ‘biological product license holder’ 
6
means— 
7
‘‘(A) the holder of an approved biological 
8
product license application for a biological prod-
9
uct; 
10
‘‘(B) a person owning or controlling en-
11
forcement of any patents that claim the biologi-
12
cal product that is the subject of such approved 
13
application; or 
14
‘‘(C) the predecessors, subsidiaries, divi-
15
sions, groups, and affiliates controlled by, con-
16
trolling, or under common control with any of 
17
the entities described in subparagraphs (A) and 
18
(B) (such control to be presumed by direct or 
19
indirect share ownership of 50 percent or great-
20
er), as well as the licensees, licensors, succes-
21
sors, and assigns of each of the entities. 
22
‘‘(9) BIOSIMILAR BIOLOGICAL PRODUCT.—The 
23
term ‘biosimilar biological product’ means the prod-
24
uct to be manufactured under the biosimilar biologi-
25
01:15 Jun 09, 2021
H2891
13 
•HR 2891 IH
cal product application that is the subject of the pat-
1
ent infringement claim. 
2
‘‘(10) BIOSIMILAR BIOLOGICAL PRODUCT APPLI-
3
CATION.—The term ‘biosimilar biological product ap-
4
plication’ means an application under section 351(k) 
5
of the Public Health Service Act (42 U.S.C. 262(k)) 
6
for licensure of a biological product as biosimilar to, 
7
or interchangeable with, a reference product. 
8
‘‘(11) BIOSIMILAR BIOLOGICAL PRODUCT APPLI-
9
CATION
FILER.—The term ‘biosimilar biological 
10
product application filer’ means a party that owns or 
11
controls a biosimilar biological product application 
12
filed with the Food and Drug Administration or has 
13
the exclusive rights under such application to dis-
14
tribute the biosimilar biological product. 
15
‘‘(12) DRUG PRODUCT.—The term ‘drug prod-
16
uct’ has the meaning given such term in section 
17
314.3(b) of title 21, Code of Federal Regulations (or 
18
any successor regulation). 
19
‘‘(13) MARKET.—The term ‘market’ means the 
20
promote, offer for sale, sell, or distribute a drug 
21
product. 
22
‘‘(14) NDA.—The term ‘NDA’ means a new 
23
drug application filed under section 505(b) of the 
24
01:15 Jun 09, 2021
H2891
14 
•HR 2891 IH
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
1
355(b)). 
2
‘‘(15) NDA HOLDER.—The term ‘NDA holder’ 
3
means— 
4
‘‘(A) the holder of an approved NDA appli-
5
cation for a drug product; 
6
‘‘(B) a person owning or controlling en-
7
forcement of the patent listed in the Approved 
8
Drug Products With Therapeutic Equivalence 
9
Evaluations (commonly known as the ‘FDA Or-
10
ange Book’) in connection with the NDA; or 
11
‘‘(C) the predecessors, subsidiaries, divi-
12
sions, groups, and affiliates controlled by, con-
13
trolling, or under common control with any of 
14
the entities described in subparagraphs (A) and 
15
(B) (such control to be presumed by direct or 
16
indirect share ownership of 50 percent or great-
17
er), as well as the licensees, licensors, succes-
18
sors, and assigns of each of the entities. 
19
‘‘(16) PARTY.—The term ‘party’ means any 
20
person, partnership, corporation, or other legal enti-
21
ty. 
22
‘‘(17) 
PATENT
INFRINGEMENT.—The 
term 
23
‘patent infringement’ means infringement of any 
24
patent or of any filed patent application, including 
25
01:15 Jun 09, 2021
H2891
15 
•HR 2891 IH
any extension, reissue, renewal, division, continu-
1
ation, continuation in part, reexamination, patent 
2
term restoration, patents of addition, and extensions 
3
thereof. 
4
‘‘(18) PATENT
INFRINGEMENT
CLAIM.—The 
5
term ‘patent infringement claim’ means any allega-
6
tion made to an ANDA filer or biosimilar biological 
7
product application filer, whether or not included in 
8
a complaint filed with a court of law, that its ANDA 
9
or ANDA product, or biological product license ap-
10
plication or biological product, may infringe any pat-
11
ent held by, or exclusively licensed to, the NDA 
12
holder or biological product license holder, biological 
13
product license holder, the ANDA filer, or biosimilar 
14
biological product application filer of the drug prod-
15
uct or biological product, as applicable. 
16
‘‘(19) STATUTORY
EXCLUSIVITY.—The term 
17
‘statutory exclusivity’ means those prohibitions on 
18
the approval of drug applications under clauses (ii) 
19
through (iv) of section 505(c)(3)(E) (5- and 3-year 
20
data exclusivity), section 527 (orphan drug exclu-
21
sivity), or section 505A (pediatric exclusivity) of the 
22
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
23
355(c)(3)(E), 360cc, 355a), or on the licensing of 
24
biological 
product 
applications 
under 
section 
25
01:15 Jun 09, 2021
H2891
16 
•HR 2891 IH
351(k)(7) (12-year exclusivity) or paragraph (2) or 
1
(3) of section 351(m) (pediatric exclusivity) of the 
2
Public Health Service Act (42 U.S.C. 262) or under 
3
section 527 of the Federal Food, Drug, and Cos-
4
metic Act (orphan drug exclusivity).’’. 
5
(b) EFFECTIVE DATE.—Section 27 of the Federal 
6
Trade Commission Act, as added by this section, shall 
7
apply to all agreements described in section 27(a)(1) of 
8
that Act entered into on or after the date of enactment 
9
of this Act. 
10
SEC. 4. NOTICE AND CERTIFICATION OF AGREEMENTS. 
11
(a) NOTICE OF ALL AGREEMENTS.—Section 1111(7) 
12
of the Medicare Prescription Drug, Improvement, and 
13
Modernization Act of 2003 (21 U.S.C. 355 note) is 
14
amended by inserting ‘‘or the owner of a patent for which 
15
a claim of infringement could reasonably be asserted 
16
against any person for making, using, offering to sell, sell-
17
ing, or importing into the United States a biological prod-
18
uct that is the subject of a biosimilar biological product 
19
application’’ before the period at the end. 
20
(b) CERTIFICATION OF AGREEMENTS.—Section 1112 
21
of the Medicare Prescription Drug, Improvement, and 
22
Modernization Act of 2003 (21 U.S.C. 355 note) is 
23
amended by adding at the end the following: 
24
01:15 Jun 09, 2021
H2891
17 
•HR 2891 IH
‘‘(d) CERTIFICATION.—The Chief Executive Officer 
1
or the company official responsible for negotiating any 
2
agreement under subsection (a) or (b) that is required to 
3
be filed under subsection (c), within 30 days after such 
4
filing, shall execute and file with the Assistant Attorney 
5
General and the Commission a certification as follows: ‘I 
6
declare that the following is true, correct, and complete 
7
to the best of my knowledge: The materials filed with the 
8
Federal Trade Commission and the Department of Justice 
9
under section 1112 of subtitle B of title XI of the Medi-
10
care Prescription Drug, Improvement, and Modernization 
11
Act of 2003, with respect to the agreement referenced in 
12
this certification— 
13
‘‘ ‘(1) represent the complete, final, and exclu-
14
sive agreement between the parties; 
15
‘‘ ‘(2) include any ancillary agreements that are 
16
contingent upon, provide a contingent condition for, 
17
or are otherwise related to, the referenced agree-
18
ment; and 
19
‘‘ ‘(3) include written descriptions of any oral 
20
agreements, representations, commitments, or prom-
21
ises between the parties that are responsive to sub-
22
section (a) or (b) of such section 1112 and have not 
23
been reduced to writing.’.’’. 
24
01:15 Jun 09, 2021
H2891
18 
•HR 2891 IH
SEC. 5. NOTIFICATION OF AGREEMENTS. 
1
Section 1112 of the Medicare Prescription Drug, Im-
2
provement, and Modernization Act of 2003 (21 U.S.C. 
3
355 note) is amended by adding at the end the following: 
4
‘‘(4) RULE OF CONSTRUCTION.— 
5
‘‘(A) An agreement that is required in sub-
6
section (a) or (b) shall include agreements re-
7
solving any outstanding disputes, including 
8
agreements resolving or settling a Patent Trial 
9
and Appeal Board proceeding. 
10
‘‘(B) For purposes of subparagraph (A), 
11
the term ‘Patent Trial and Appeal Board pro-
12
ceeding’ means a proceeding conducted by the 
13
United States Patent and Trademark Office 
14
Patent Trial and Appeal Board, including but 
15
not limited to inter parties review, post-grant 
16
review, the transitional program for covered 
17
business method patents, and derivation pro-
18
ceedings.’’. 
19
SEC. 6. FORFEITURE OF 180-DAY EXCLUSIVITY PERIOD. 
20
Section 505(j)(5)(D)(i)(V) of the Federal Food, 
21
Drug, and Cosmetic Act (21 U.S.C. 355(j)(5)(D)(i)(V)) 
22
is amended by inserting ‘‘section 27 of the Federal Trade 
23
Commission Act or’’ after ‘‘that the agreement has vio-
24
lated’’. 
25
01:15 Jun 09, 2021
H2891
19 
•HR 2891 IH
SEC. 7. COMMISSION LITIGATION AUTHORITY. 
1
Section 16(a)(2) of the Federal Trade Commission 
2
Act (15 U.S.C. 56(a)(2)) is amended— 
3
(1) in subparagraph (D), by striking ‘‘or’’ after 
4
the semicolon; 
5
(2) in subparagraph (E), by inserting ‘‘or’’ 
6
after the semicolon; and 
7
(3) inserting after subparagraph (E) the fol-
8
lowing: 
9
‘‘(F) under section 27;’’. 
10
SEC. 8. REPORT ON ADDITIONAL EXCLUSION. 
11
Within 1 year of enactment, the Federal Trade Com-
12
mission shall provide a recommendation, and the Commis-
13
sion’s basis for it, to the Committee on the Judiciary of 
14
the House of Representatives and the Committee on the 
15
Judiciary of the Senate regarding a potential amendment 
16
to include in section 27(c) of the Federal Trade Commis-
17
sion Act, an additional exclusion for consideration granted 
18
by an NDA holder or biological product license holder to 
19
the ANDA filer or biosimilar biological product application 
20
filer, respectively, as part of the resolution or settlement, 
21
a release, waiver, or limitation of a claim for damages or 
22
other monetary relief. 
23
SEC. 9. STATUTE OF LIMITATIONS. 
24
The Federal Trade Commission shall commence any 
25
enforcement proceeding described in section 27 of the 
26
01:15 Jun 09, 2021
H2891
20 
•HR 2891 IH
Federal Trade Commission Act, as added by section 3, ex-
1
cept for an action described in section 27(f)(2) of the Fed-
2
eral Trade Commission Act, not later than 6 years after 
3
the date on which the parties to the agreement file the 
4
certification under section 1112(d) of the Medicare Pre-
5
scription Drug, Improvement, and Modernization Act of 
6
2003 (21 U.S.C. 355 note). 
7
SEC. 10. SEVERABILITY. 
8
If any provision of this Act, an amendment made by 
9
this Act, or the application of such provision or amend-
10
ment to any person or circumstance is held to be unconsti-
11
tutional, the remainder of this Act, the amendments made 
12
by this Act, and the application of the provisions of such 
13
Act or amendments to any person or circumstance shall 
14
not be affected. 
15
Æ 
01:15 Jun 09, 2021
H2891
